Glaxo, Valeant Epilepsy Drug Rejected by U.S. FDA
This article is for subscribers only.
GlaxoSmithKline Plc and Valeant Pharmaceuticals International Inc.’s experimental epilepsy drug was rejected by U.S. regulators for “nonclinical” reasons, the companies said.
Glaxo, based in London, and Valeant, based in Mississauga, Ontario, are evaluating the Food and Drug Administration’s decision not to approve the medicine, ezogabine, the companies said today in a statement. Glaxo, the U.K.’s biggest drugmaker, bought global marketing rights to the product from Valeant in